# Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

> **NCT04287894** · PHASE1 · TERMINATED · sponsor: **The Netherlands Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Stage III NSCLC

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **RADIATION:** chemo radiotherapy
- **PROCEDURE:** Resection

## Key facts

- **NCT ID:** NCT04287894
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-28
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-04
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy)
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287894, "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04287894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*